Massachusetts Medical Society workforce survey (600 MDs) shows that >half have cut back patient time, 55% admitted to burnout (more in women), & 1 in 4 physicians plan to leave medicine in the next two years. https://t.co/VUd101BrEi https://t.co/Hc6UyGMW1E

Periodontal Mucosal Breaks Trigger RA Disease Activity Periodontal disease (PD) is more common in RA, especially those with anti-citrullinated protein antibodies (ACPAs). RA activity has been linked to the severity of PD and mucosal inflammation. https://t.co/Yx7fPMrB7v https://t.co/pH0XGPqGhJ

Drs Schett & Mackensen reported a case of refractory inflammatory myositis successfully treated with CD19 CAR T cells. 41yoM w/ +Jo-1, myositis, ILD, Raynauds, periorb edema, not responding to steroids, RTX, IVIG, tacrolimus, CTX https://t.co/DlKs3DGWNu https://t.co/M7qrcfcE2y

Study of 78 pt suspected of #GCA undergoing Temp. artery Bx and US. Nearly half (35) Dx w/ GCA. Both had similar sensitivities(69% and 63%, respectively), but specificity higher w/ biopsy (100% vs 79%). Compression sign had best diagnostic performance https://t.co/wzVqrHvfqM https://t.co/HRmfb6g7aF

Is it Lupus? https://t.co/dsHQvyuCtC https://t.co/JBYGAWQJ7X

Phase 3 Trials of Baricitinib Disappoint in SL Despite the encouraging phase II trial results of baricitinib in SLE patients, two parallel phase III trials have failed to redemonstrate the efficacy of baricitinib in active SLE. https://t.co/SwU7ujZnsP https://t.co/IgpCTtyDNA

While anifrolumab targets IFN alfa in SLE, its unclear how much IFNa is needed for Rx response. A study of 40 pts shows Rx naive SLE has signif higher serum IFN activity; this is assoc w/ fever, leukopenia, ALE rash and oral ulcers & more organ damage https://t.co/nhqg0ky7RT https://t.co/kBuqvJYFYE

"My eye is swollen": an underrecognized mimic of IgG4-related disease Artem Minalyan, MD, presenting his poster at RWCS 2023. https://t.co/N2VShY5OHY https://t.co/fQYbFH6Mnb

Treat-to-Target Guidelines for GCA and PMR The Annals of Rheumatic Disease has published updated multinational, T2T recommendations for the treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR). https://t.co/zb0PXsW5mw https://t.co/PdFd9A794O

FDA has approved sarilumab (Kevzara) for the treatment of polymyalgia rheumatica (PMR) in adult patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. Approval is based on Phase 3 SAPHYR study https://t.co/7GHG2uG9yQ https://t.co/MZ7RYGdDfG